2022
Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS
O'Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, Nimmo C, Baldwin M, Boodhram R, Maharaj B, Amico KR, Naidoo K, Friedland G. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 325-332. PMID: 35195572, PMCID: PMC11077859, DOI: 10.1097/qai.0000000000002940.Peer-Reviewed Original ResearchConceptsMDR-TB treatment outcomesResistance-associated variantsTreatment outcomesAntiretroviral therapyMDR-TBART adherenceMultidrug-resistant tuberculosis treatmentHIV treatment outcomesProspective cohort studyMultidrug-resistant tuberculosisEnd of treatmentTreatment of patientsSuccessful treatment outcomeElectronic dose monitoring devicesHIV/AIDSCohort studyClinical outcomesMultivariable analysisNovel regimensMedication adherenceAdherence thresholdTuberculosis treatmentTreatment completionLow adherenceDose monitoring
2014
Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 147-154. PMID: 24429305, PMCID: PMC4770013, DOI: 10.5588/ijtld.13.0627.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB patientsSequential treatment armAnti-tuberculosis treatmentAntiretroviral treatmentTreatment armsFirst-line anti-tuberculosis treatmentMultidrug-resistant tuberculosis patientsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionOut-patient clinicDrug susceptibility resultsSAPiT trialTuberculosis patientsClinical outcomesEarly initiationTherapeutic effectVirus infectionMortality ratePatientsTherapeutic outcomesSmall sample sizeTreatmentSusceptibility resultsTuberculosis
2006
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV
Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. Journal Of Antimicrobial Chemotherapy 2006, 58: 1299-1302. PMID: 17032686, DOI: 10.1093/jac/dkl399.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAntibiotics, AntitubercularAnti-HIV AgentsBenzoxazinesCD4 Lymphocyte CountChromatography, High Pressure LiquidCyclopropanesDidanosineDrug Therapy, CombinationFemaleHIV InfectionsHumansLamivudineLongitudinal StudiesMaleOxazinesRifampinTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsExcellent clinical outcomesEfavirenz concentrationsClinical outcomesAntiretroviral therapyEfavirenz levelsAfrican patientsNon-detectable viral loadSmear-positive pulmonary TBLong-term clinical outcomesAdministration of efavirenzCD4 cell increaseHIV clinical outcomesPlasma efavirenz concentrationsCells/mm3Half of patientsTB regimenPulmonary TBPharmacokinetic interactionsTB outcomesTherapy completionRifampicin administrationViral loadTherapeutic rangePatientsHIV